GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...

Boston Scientific (NYSE:BSX – Get Free Report) had its price objective lifted by equities research analysts at Raymond James ...

New Delhi, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The global neurostimulation devices market was valued at US$ 9.84 billion in 2024 and is expected to reach US$ 22.64 billion by 2033 from, growing at a ...

Boston Scientific Corporation develops ... neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency ...

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...

Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...